147 related articles for article (PubMed ID: 2474382)
41. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
42. [Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Siegert W; Huhn D; Neubauer A; Brittinger G; Engelhard M; Gerhartz H; Heinz R; Meusers P; Stacher A; Thiel E
Onkologie; 1988 Feb; 11(1):30-4. PubMed ID: 2452392
[TBL] [Abstract][Full Text] [Related]
43. [Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Gerhartz HH; Wilmanns W; Brittinger G; Engelhard M; Heinz R; Huhn D; Meusers P; Siegert W; Stacher A; Thiel E
Onkologie; 1989 Feb; 12(1):22-6. PubMed ID: 2470000
[TBL] [Abstract][Full Text] [Related]
44. [Aclarubicin-combined combination chemotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma].
Sampi K; Masaoka T; Takagi T; Sakamoto S; Mikuni C; Kano Y
Gan To Kagaku Ryoho; 1989 Jan; 16(1):79-82. PubMed ID: 2643395
[TBL] [Abstract][Full Text] [Related]
45. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
[TBL] [Abstract][Full Text] [Related]
46. Non-hodgkins lymphoma.
Mead G; Woodcock J; Young C
Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
[No Abstract] [Full Text] [Related]
47. German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
Gerhartz HH; Thiel E; Brittinger G; Dörken B; Engelhard M; Engert W; Enne W; Fuchs R; Hagen-Aukamp CH; Huhn D
Blut; 1988 Mar; 56(3):139-42. PubMed ID: 2451551
[No Abstract] [Full Text] [Related]
48. Third generation chemotherapy with P-VABEC for aggressive non-Hodgkin's lymphomas of the elderly.
Caracciolo F; Petrini M; Capochiani E; Papineschi F; Grassi B
Leuk Lymphoma; 1993 Sep; 11(1-2):115-8. PubMed ID: 8220144
[TBL] [Abstract][Full Text] [Related]
49. Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas.
Fridrik MA; Hausmaninger H; Michlmayr G; Haidinger R; Seewann HL; Lehnert M
Hematol Oncol; 1991; 9(4-5):209-15. PubMed ID: 1743623
[TBL] [Abstract][Full Text] [Related]
50. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
[TBL] [Abstract][Full Text] [Related]
51. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
52. P-COMM-B induction chemotherapy in intermediate and high grade non-Hodgkin's lymphoma.
Phillips JK; Sherlaw-Johnson C; Davies JM; Clough JV; Parry H; Nash JR; Cawley JC
Leuk Lymphoma; 1995 Jun; 18(1-2):137-43. PubMed ID: 8580816
[TBL] [Abstract][Full Text] [Related]
53. MACOP-B regimen in non-Hodgkin's lymphoma.
Joensuu H; Turpeenniemi-Hujanen T
Acta Oncol; 1992; 31(6):657-61. PubMed ID: 1281651
[TBL] [Abstract][Full Text] [Related]
54. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
[TBL] [Abstract][Full Text] [Related]
55. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
56. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
57. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L
Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334
[TBL] [Abstract][Full Text] [Related]
58. [Non-Hodgkin's lymphomas. Results of alternating chemotherapy versus sequential chemotherapy].
Avilés A; Díaz-Maqueo JC; Torras V; Rodríguez L; López Vancell D
Sangre (Barc); 1990 Aug; 35(4):245-9. PubMed ID: 1703327
[TBL] [Abstract][Full Text] [Related]
59. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs.
Salles G; Herbrecht R; Tilly H; Berger F; Brousse N; Gisselbrecht C; Coiffier B
Am J Med; 1991 Jan; 90(1):77-84. PubMed ID: 1702581
[TBL] [Abstract][Full Text] [Related]
60. EMOP/CA chemotherapy for the treatment of aggressive non-Hodgkin's lymphomas.
Smith DB; Ledermann JA; Boesen E; Newlands ES; Begent RH; Rustin GJ; Glaser MG; Bagshawe KD
Eur J Cancer Clin Oncol; 1989 Jun; 25(6):991-4. PubMed ID: 2753060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
